- 主题
- 386
- 您的身份
- 病友
- 就诊医院
- 北京协和
- 病理报告
- 滤泡性淋巴瘤1-2级
- 目前状态
- 康复10-20年
参加活动:0 次 组织活动:0 次
您的身份病友
病理报告滤泡性淋巴瘤1-2级
就诊医院北京协和
目前状态康复10-20年
最后登录2025-6-25
  
|
NCCN指南2025年第2版中,对于双重打击淋巴瘤,无预设条件推荐的方案其实只有一个,那就是DA-EPOCH-R方案。
HGBL with MYC and BCL2 rearrangements with or without BCL6 rearrangements (ICC)
Treatment options
•Clinical trial is recommended.
•Consolidative ISRT is preferred for localized disease.
While the optimal treatment approach is not established, the following induction regimens have been used:
DA-EPOCH-R
RCHOP may be associated with a suboptimal outcome. Could be considered for patients with low risk disease (IPI <2).
R-mini-CHOP may be considered for patients who are frail or older
Potentially toxic regimens; performance status and comorbidities should be considered:
◊R-HyperCVAD
◊R-CODOX-M/R-IVAC |
|